340B Transparency Act

The Bill 118 hr 3290, also known as the 340B Transparency Act, aims to increase transparency and accountability in the 340B Drug Pricing Program. This program requires drug manufacturers to provide discounts on outpatient drugs to certain healthcare facilities that serve low-income and vulnerable populations.

The bill requires the Department of Health and Human Services (HHS) to establish a publicly accessible website that provides information on the 340B program, including the prices paid by covered entities for drugs purchased through the program. This information will help ensure that the program is being used as intended and that the discounts provided by drug manufacturers are being passed on to patients in need.

Additionally, the bill requires covered entities to report certain information to HHS, including the total amount of discounts received through the program and how those discounts are being used. This reporting requirement will help HHS monitor the program and ensure that it is effectively serving its intended purpose. Overall, the 340B Transparency Act aims to increase transparency and accountability in the 340B Drug Pricing Program, ultimately ensuring that low-income and vulnerable populations have access to affordable medications.